Lymphoma & Myeloma 2013

 
 
 

Lymphoma & Myeloma 2013 took place October 24-26 in New York, New York.

 

Chemo most likely out for CLL patients with del17p

Erilyn Riley Read Article
Published: 11/29/13

chemotherapy_drug_nurse_hanging_Credit_Bill_Branson_220.jpg
A nurse hangs bags containing
chemotherapy drugs
Credit: Bill Branson

Patients with chronic lymphocytic leukemia (CLL) and 17p deletion (del17p) pose a dilemma for physicians because there is no clear standard of care. Chemotherapy doesn’t work well because it needs p53 to be active. And progression-free survival (PFS) is about the same with FCR (fludarabine, cyclophosphamide, rituximab) and alemtuzumab. “If there were a clear, obvious standard of care, people wouldn’t be arguing,” said Susan O’Brien . . . [Read Article]

Allo transplant ‘may not be dead’ for patients with MM

Erilyn Riley Read Article
Published: 11/05/13

Koehne_Guenther_MDPhD_L-M2013_240.jpg
Guenther Koehne, MD, PhD

Results of a phase 2 trial reported at Lymphoma & Myeloma 2013 indicate that T-cell-depleted (TCD) allogeneic stem cell transplant reduces transplant-related mortality and can eliminate chronic graft-versus-host disease (GVHD) in patients with multiple myeloma (MM). Guenther Koehne, MD, PhD, of Memorial Sloan-Kettering Cancer Center in New York, presented the data, saying that “you may not need to go after cure in this disease, but I think we should at least try.” [Read Article]

Urgent need for MRD consensus guidelines in myeloma

Erilyn Riley Read Article
Published: 10/30/13

Landgren_C_Ola_MD_PhD_LM2013_strt_245.jpg
C. Ola Landgren, MD, PhD

A recent survey of US flow cytometry labs revealed that fewer than half perform minimal residual disease (MRD) analysis in multiple myeloma (MM). And of those that do, few labs use the first aspirate, 5 use gating strategies that have low precision, and 1 lab doesn’t use an antibody considered to be essential. “Clearly, there is a lot of work to be done across the country” in terms of standardizing MRD analysis in MM, said C. Ola Landgren, MD, PhD, of the National Cancer Institute in Bethesda, Maryland. [Read Article]

    {title}

    {icon} {author} Read Article
    Published: {pubDate}

    {summary}